Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RXRX Stock Chart & Stats
$6.30
-$0.34(-4.54%)
At close: 4:00 PM EST
$6.30
-$0.34(-4.54%)
Day’s Range― - ―
52-Week Range$3.79 - $12.36
Previous CloseN/A
Volume5.68M
Average Volume (3M)58.42M
Market Cap
$2.63B
Enterprise Value$1.67B
Total Cash (Recent Filing)$528.22M
Total Debt (Recent Filing)$88.08M
Price to Earnings (P/E)―
Beta3.28
Next Earnings
Nov 05, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding427,312,960
10 Day Avg. Volume90,849,581
30 Day Avg. Volume58,418,048
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue25.94
Enterprise Value/Gross Profit-690.22
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$6.93Price Target Upside10.00% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial EfficiencyRecent cost-cutting measures are expected to lower operational expenses by approximately 35%, which is likely to improve financial efficiency.
Partnerships And CollaborationsManagement expects large pharma will continue to rely on TechBio companies such as Recursion despite recent efforts to build out internal AI/ML capabilities, and views RXRX as the only public name of sufficient heft.
Revenue OpportunitiesRXRX achieved a $7mm discovery milestone under the Sanofi collaboration for lead series development of an immunology target.
Bears Say
Analyst RatingsAnalyst reduced the price target from $4 to $3 and reiterated a market perform rating.
Pipeline DecisionsRXRX announced discontinuation of its most advanced pipeline assets.
Research And Development CostsR&D expenses of $128.6mm were significantly above the consensus expectations.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $3.79 and its highest was $12.36 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $2.63B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 7 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.353 by -$0.057.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 427,312,960 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.353. Following the earnings report the stock price went down -4.655%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
Recursion Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.93 (10.00% Upside)
$6.93 (10.00% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $223.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.77%
12-Months-Change
Fundamentals
Return on Equity
-86.34%
Trailing 12-Months
Asset Growth
67.86%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals (RXRX) is a biotechnology company that leverages advanced machine learning and high-throughput biology to discover and develop new therapeutics for various diseases. Focused primarily on rare genetic conditions and other complex diseases, Recursion employs its proprietary platform to analyze biological data, enabling the rapid identification of drug candidates. The company operates at the intersection of technology and life sciences, utilizing its core capabilities in data analysis and biological experimentation to advance its drug development pipeline.
RXRX Company Deck
RXRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in technology and partnerships, showcasing Recursion's innovative approach and strong cash management. However, there are concerns regarding long drug development timelines, regulatory uncertainties, and reliance on partnerships for revenue.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$6.93
▲(10.00% Upside)
Technical Analysis
Agios Pharma
―
Galapagos
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
3.60% Insiders
12.36% Mutual Funds
0.03% Other Institutional Investors
60.49% Public Companies and Individual Investors